Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables: 2010-2024

Historic Receivables for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $13.8 million.

  • China Pharma Holdings' Receivables fell 97.51% to $355,789 in Q3 2025 from the same period last year, while for Sep 2025 it was $42.1 million, marking a year-over-year decrease of 25.95%. This contributed to the annual value of $13.8 million for FY2024, which is 4.14% down from last year.
  • Per China Pharma Holdings' latest filing, its Receivables stood at $13.8 million for FY2024, which was down 4.14% from $14.4 million recorded in FY2023.
  • China Pharma Holdings' Receivables' 5-year high stood at $14.4 million during FY2023, with a 5-year trough of $450,670 in FY2022.
  • Over the past 3 years, China Pharma Holdings' median Receivables value was $13.8 million (recorded in 2024), while the average stood at $9.6 million.
  • As far as peak fluctuations go, China Pharma Holdings' Receivables slumped by 78.94% in 2022, and later surged by 3,106.00% in 2023.
  • Yearly analysis of 5 years shows China Pharma Holdings' Receivables stood at $1.2 million in 2020, then skyrocketed by 72.24% to $2.1 million in 2021, then tumbled by 78.94% to $450,670 in 2022, then soared by 3,106.00% to $14.4 million in 2023, then decreased by 4.14% to $13.8 million in 2024.